Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis
NCT ID: NCT00658788
Last Updated: 2022-08-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
305 participants
INTERVENTIONAL
2008-03-31
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis
NCT00988637
Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis
NCT00733954
Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis
NCT00437216
Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp
NCT00881868
Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis
NCT01205880
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study Treatment
clobetasol propionate spray 0.05%
Other Names:
Clobex® Spray 0.05% clobetasol propionate spray, 0.05%, applied topically twice daily
calcitriol ointment
Other Names:
Calcitriol Ointment calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily
clobetasol propionate spray 0.05%
clobetasol propionate spray, 0.05%, applied topically twice daily
calcitriol ointment
calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
clobetasol propionate spray 0.05%
clobetasol propionate spray, 0.05%, applied topically twice daily
calcitriol ointment
calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Overall Disease Severity of at least 3 (moderate)
Exclusion Criteria
* Psoriasis involving only the scalp, groin, axillae, and/or other intertriginous areas
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galderma R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronald W Gottschalk, MD
Role: STUDY_DIRECTOR
Galderma R&D
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Therapeutics Clinical Research
San Diego, California, United States
MedaPhase, Inc.
Newnan, Georgia, United States
Gwinnett Clinical Research Center, Inc
Snellville, Georgia, United States
Hudson Dermatology
Evansville, Indiana, United States
Mount Sinai Department of Dermatology
New York, New York, United States
Northeastern Ohio Universities College of Medicine
Warren, Ohio, United States
Central Sooner Research
Norman, Oklahoma, United States
J&J Studies, Inc
College Station, Texas, United States
Suzanne Bruce and Associates, PA
Houston, Texas, United States
Virginia Clinical Research, Inc
Norfolk, Virginia, United States
Dermatology Associates of Seattle, PLLC
Seattle, Washington, United States
Madison Skin and Research, Inc
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
US10085
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.